{"id":19813,"date":"2024-12-12T06:59:32","date_gmt":"2024-12-12T05:59:32","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2024\/12\/12\/il-33-is-associated-with-alveolar-dysfunction-in-patients-with-viral-lower-respiratory-tract-disease-ian-c-scott\/"},"modified":"2024-12-12T06:59:32","modified_gmt":"2024-12-12T05:59:32","slug":"il-33-is-associated-with-alveolar-dysfunction-in-patients-with-viral-lower-respiratory-tract-disease-ian-c-scott","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2024\/12\/12\/il-33-is-associated-with-alveolar-dysfunction-in-patients-with-viral-lower-respiratory-tract-disease-ian-c-scott\/","title":{"rendered":"IL-33 is associated with alveolar dysfunction in patients with viral lower respiratory tract disease. Ian C Scott"},"content":{"rendered":"<div>\n<p>Mucosal Immunol. 2024 Dec 9:S1933-0219(24)00124-7. doi: 10.1016\/j.mucimm.2024.12.001. Online ahead of print.<\/p>\n<p>ABSTRACT<\/p>\n<p>Interleukin (IL)-33 is released following tissue damage, causing airway inflammation and remodelling via reduced IL-33 (IL-33red)\/serum stimulation-2 (ST2) and oxidised IL-33 (IL-33ox)\/receptor for advanced glycation end products (RAGE)\/epidermal growth factor receptor (EGFR) pathways. This study aimed to identify associations of IL-33 with clinical outcomes and pathological mechanisms during viral lower respiratory tract disease (LRTD). Ultra-sensitive immunoassays were developed to measure IL-33red, IL-33ox and IL-33\/sST2 complexes in samples from patients hospitalised with COVID-19. Immunohistochemistry and multiomics were used to characterise lung samples. Elevated IL-33 in the airway and IL-33\/sST2 complex in the circulation correlated with poor clinical outcomes (death, need for intensive care or mechanical ventilation). IL-33 was localised to airway epithelial and endothelial barriers, whereas IL1RL1 was expressed on aerocytes, alveolar endothelial cells specialised for gaseous exchange. IL-33 increased expression of mediators of neutrophilic inflammation, immune cell infiltration, interferon signalling and coagulation in endothelial cell cultures. Endothelial IL-33 signatures were strongly related with signatures associated with viral LRTD. Increased IL-33 release following respiratory viral infections is associated with poor clinical outcomes and might contribute to alveolar dysfunction. Although this does not show a causal relationship with disease, these results provide a rationale to evaluate pathological roles for IL-33 in viral LRTD.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39662674\/?utm_source=WordPress&amp;utm_medium=rss&amp;utm_content=101299742&amp;ff=20241212005931&amp;v=2.18.0.post9+e462414\">39662674<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1016\/j.mucimm.2024.12.001\">10.1016\/j.mucimm.2024.12.001<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Mucosal Immunol. 2024 Dec 9:S1933-0219(24)00124-7. doi: 10.1016\/j.mucimm.2024.12.001. Online ahead of print. ABSTRACT Interleukin (IL)-33 is released following tissue damage, causing airway inflammation and remodelling via reduced IL-33 (IL-33red)\/serum stimulation-2 (ST2) and oxidised IL-33 (IL-33ox)\/receptor for advanced glycation end products (RAGE)\/epidermal growth factor receptor (EGFR) pathways. This study aimed to identify associations of IL-33 with clinical &#8230; <a title=\"IL-33 is associated with alveolar dysfunction in patients with viral lower respiratory tract disease. Ian C Scott\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2024\/12\/12\/il-33-is-associated-with-alveolar-dysfunction-in-patients-with-viral-lower-respiratory-tract-disease-ian-c-scott\/\" aria-label=\"Read more about IL-33 is associated with alveolar dysfunction in patients with viral lower respiratory tract disease. Ian C Scott\">Read more<\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[57,42],"tags":[],"class_list":["post-19813","post","type-post","status-publish","format-standard","hentry","category-mucosal-immunology","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/19813","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=19813"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/19813\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=19813"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=19813"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=19813"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}